Prof Masakazu Toi speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the combination of S-1 with endocrine therapy for patients with hormone receptor-positive, HER2-negative breast cancer.
He describes the design of the trial which evaluated endocrine treatment plus S-1 (an an oral fluoropyrimidine-based drug), versus endocrine treatment alone.
Prof Toi outlines the main results from this study and the action of S-1.
For the future, he believes this study should be expanded and include additional countries and genomic testing will be incorporated to select patients.
Watch the press conference here.
Read more about the study here.